It's difficult to call a stock with an EV/EBITDA ratio in the 20's and more than a dozen active sell-side analysts "undiscovered", but I'm surprised at the relative level of chatter about Volcano (VOLC) in comparison to names like Intuitive Surgical (ISRG), MAKO Surgical (MAKO), or Abiomed (ABMD). While Volcano arguably suffers from the fact that its addressed markets have been around quite a bit longer, I believe growth-oriented investors ought to take another look at some of the possibilities of Volcano finding a new level of market acceptance and growth in the coming years.
A Clearer Picture Means Better Outcomes
Volcano has long been in the business of intravascular imaging, specifically...
Only subscribers can access this article, which is part of the PRO research library covering 3,618 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: